PPARG and myeloid sarcoma: In contrast, administration of PPAR-γ ligand 15d-PGJ2 reduced the severity of EAE by inhibiting the activation and expansion of encephalitogenic T cells, which suggests that PPAR-γ agonists may act as a new therapeutic strategy for MS in which thyroid hormones are most probably involved [66,67,68].